These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
315 related items for PubMed ID: 9855155
21. Effects of systemic administration of 0.5% tropicamide on intraocular pressure, pupillary diameter, blood pressure, and heart rate in normal cats. Schmidt KS, Hacker DV, Kass PH, Barkhoodarian AL. Vet Ophthalmol; 2006; 9(2):137-9. PubMed ID: 16497239 [Abstract] [Full Text] [Related]
22. Discrepancy of the intraocular pressure response between fellow eyes in one-eye trials versus bilateral treatment: verification with normal subjects. Takahashi M, Higashide T, Sakurai M, Sugiyama K. J Glaucoma; 2008; 17(3):169-74. PubMed ID: 18414100 [Abstract] [Full Text] [Related]
23. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. Trinquand C, Romanet JP, Nordmann JP, Allaire C, Groupe d'étude. J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585 [Abstract] [Full Text] [Related]
24. Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys. Wang RF, Gagliuso DJ, Podos SM. J Glaucoma; 2008 Feb; 17(1):73-8. PubMed ID: 18303390 [Abstract] [Full Text] [Related]
31. Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study. Mansouri K, Silva SE, Shaarawy T. J Glaucoma; 2011 Oct; 20(8):519-22. PubMed ID: 21048514 [Abstract] [Full Text] [Related]
35. The effects of betaxolol hydrochloride ophthalmic solution on intraocular pressures during transient microgravity. Pattinson TJ, Gibson CR, Manuel FK, Bishop SL, March WF. Aviat Space Environ Med; 1999 Oct; 70(10):1012-7. PubMed ID: 10519481 [Abstract] [Full Text] [Related]
36. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R. Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191 [Abstract] [Full Text] [Related]
38. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. Inan UU, Ermis SS, Orman A, Onrat E, Yucel A, Ozturk F, Asagidag A, Celik A. J Ocul Pharmacol Ther; 2004 Aug; 20(4):293-310. PubMed ID: 15321024 [Abstract] [Full Text] [Related]